Failed central nervous system regeneration - A downside of immune privilege?

被引:50
作者
Bechmann, I [1 ]
机构
[1] Charite Univ Med Berlin, Ctr Anat, Inst Cell Biol & Neurobiol, Dept Expt Neuroimmunol, D-10098 Berlin, Germany
关键词
immune privilege; (tolerogenic) antigen presentation; microglia; astrocytes; CD95L (FasL); organ-specific immunity;
D O I
10.1385/NMM:7:3:217
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Immunity is required to eliminate dangerous or degenerated material and to support regeneration, but also causes significant parenchymal damage. In the eye and the brain, in which cornea and lens poorly regenerate and neurons are hardly replaceable, early transplantation experiments demonstrated remarkable tolerance to various grafts. This "immunologically privileged status" (Billingham and Boswell, 1953) may reflect evolutionary pressure to down-modulate certain actions of immune cells within particularly vulnerable tissues. As an example, tolerating certain "neurotrophic" viruses may often be a more successful strategy for survival than the elimination of all infected neurons. While several constitutive and inducible signals maintaining or re-establishing immune tolerance within the brain have been identified, it has also become evident that the resulting anti-inflammatory environment limits certain beneficial effects of neuroinflammation such as neurotrophin secretion or glutamate buffering by T-cells and the clearance of growth-inhibiting myelin or amyloid. Following spinal cord injury, the costs and benefits of neuroinflammation seem to come close because enhancing as well as suppressing innate or adaptive immunity caused amelioration and aggravation of functional regeneration in similar experiments. Evaluating such balances has also begun in (animal models of) Alzheimer's disease, central nervous system trauma, and stroke, and the appreciation of the beneficial side of neuroinflammation has caused a rethinking of the ill-defined use of immune suppressants. As dual roles for individual molecules have been recognized (Merrill and Benveniste, 1996), we are uncovering an already fine-tuned system, but the challenge remains to further support beneficial immune cascades without causing additional damage, and vice versa.
引用
收藏
页码:217 / 228
页数:12
相关论文
共 131 条
[1]
Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL [J].
Aktas, O ;
Smorodchenko, A ;
Brocke, S ;
Infante-Duarte, C ;
Topphoff, US ;
Vogt, J ;
Prozorovski, T ;
Meier, S ;
Osmanova, V ;
Pohl, E ;
Bechmann, I ;
Nitsch, R ;
Zipp, F .
NEURON, 2005, 46 (03) :421-432
[2]
Glia-T cell dialogue [J].
Aloisi, F ;
Serafini, B ;
Adorini, L .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 107 (02) :111-117
[3]
Babcock AA, 2003, J NEUROSCI, V23, P7922
[4]
BARKER CF, 1977, ADV IMMUNOL, V25, P1
[5]
Apoptosis in brain-specific autoimmune disease [J].
Bauer, J ;
Wekerle, H ;
Lassmann, H .
CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (06) :839-843
[6]
Becher B, 2000, GLIA, V29, P293
[7]
Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO
[8]
2-S
[9]
Turnover of rat brain perivascular cells [J].
Bechmann, I ;
Kwidzinski, E ;
Kovac, AD ;
Simbürger, E ;
Horvath, T ;
Gimsa, U ;
Dirnagl, U ;
Priller, J ;
Nitsch, R .
EXPERIMENTAL NEUROLOGY, 2001, 168 (02) :242-249
[10]
Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia [J].
Bechmann, I ;
Goldmann, J ;
Kovac, AD ;
Kwidzinski, E ;
Simbürger, E ;
Naftolin, F ;
Dirnagl, U ;
Nitsch, R ;
Priller, J .
FASEB JOURNAL, 2005, 19 (01) :647-+